Chabot-Fletcher M[au] - Search Results

Year	Number of Results
1993	2
1994	2
1995	4
1996	6
1997	3
1998	3
1999	2
2000	3
2009	1
2021	0

1

The genetics of a pharma merger.

Sanseau P, Chabot-Fletcher M, Browne MJ. Sanseau P, et al. Among authors: chabot fletcher m. Drug Discov Today. 2009 Apr;14(7-8):334-6. doi: 10.1016/j.drudis.2008.12.001. Epub 2009 Jan 21. Drug Discov Today. 2009. PMID: 19121408

2

Inhibition of CoA-independent transacylase reduces inflammatory lipid mediators.

Winkler JD, Fonteh AN, Sung CM, Huang L, Chabot-Fletcher M, Marshall LA, Chilton FH. Winkler JD, et al. Among authors: chabot fletcher m. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:89-91. Adv Prostaglandin Thromboxane Leukot Res. 1995. PMID: 7732911 Review. No abstract available.

3

Evaluation of the cutaneous anti-inflammatory activity of azaspiranes.

Griswold DE, Martin LD, Badger AM, Breton J, Chabot-Fletcher M. Griswold DE, et al. Among authors: chabot fletcher m. Inflamm Res. 1998 Feb;47(2):56-61. doi: 10.1007/s000110050270. Inflamm Res. 1998. PMID: 9535542

4

The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-kappaB.

Breton JJ, Chabot-Fletcher MC. Breton JJ, et al. Among authors: chabot fletcher mc. J Pharmacol Exp Ther. 1997 Jul;282(1):459-66. J Pharmacol Exp Ther. 1997. PMID: 9223588

5

1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.

Boehm JC, Smietana JM, Sorenson ME, Garigipati RS, Gallagher TF, Sheldrake PL, Bradbeer J, Badger AM, Laydon JT, Lee JC, Hillegass LM, Griswold DE, Breton JJ, Chabot-Fletcher MC, Adams JL. Boehm JC, et al. Among authors: chabot fletcher mc. J Med Chem. 1996 Sep 27;39(20):3929-37. doi: 10.1021/jm960415o. J Med Chem. 1996. PMID: 8831759

6

Inhibition of NFkappaB-mediated interleukin-1beta-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine.

Roshak A, Jackson JR, Chabot-Fletcher M, Marshall LA. Roshak A, et al. Among authors: chabot fletcher m. J Pharmacol Exp Ther. 1997 Nov;283(2):955-61. J Pharmacol Exp Ther. 1997. PMID: 9353419

7

Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth.

Harrop JA, McDonnell PC, Brigham-Burke M, Lyn SD, Minton J, Tan KB, Dede K, Spampanato J, Silverman C, Hensley P, DiPrinzio R, Emery JG, Deen K, Eichman C, Chabot-Fletcher M, Truneh A, Young PR. Harrop JA, et al. Among authors: chabot fletcher m. J Biol Chem. 1998 Oct 16;273(42):27548-56. doi: 10.1074/jbc.273.42.27548. J Biol Chem. 1998. PMID: 9765287 Free article.

8

Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma.

Chabot-Fletcher MC, Underwood DC, Breton JJ, Adams JL, Kagey-Sobotka A, Griswold DE, Marshall LA, Sarau HM, Winkler JD, Hay DW. Chabot-Fletcher MC, et al. J Pharmacol Exp Ther. 1995 Jun;273(3):1147-55. J Pharmacol Exp Ther. 1995. PMID: 7791085

9

cDNA sequence and characterization of the gene that encodes human myotrophin/V-1 protein, a mediator of cardiac hypertrophy.

Anderson KM, Berrebi-Bertrand I, Kirkpatrick RB, McQueney MS, Underwood DC, Rouanet S, Chabot-Fletcher M. Anderson KM, et al. Among authors: chabot fletcher m. J Mol Cell Cardiol. 1999 Apr;31(4):705-19. doi: 10.1006/jmcc.1998.0903. J Mol Cell Cardiol. 1999. PMID: 10329199

10

Effects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators.

Winkler JD, Fonteh AN, Sung CM, Heravi JD, Nixon AB, Chabot-Fletcher M, Griswold D, Marshall LA, Chilton FH. Winkler JD, et al. Among authors: chabot fletcher m. J Pharmacol Exp Ther. 1995 Sep;274(3):1338-47. J Pharmacol Exp Ther. 1995. PMID: 7562506

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results